Taspoglutide: a long acting human glucagon-like polypeptide-1 analogue
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Taspoglutide (R1583/BIM51077) is a new anti diabetic drug from Hoffmann-La Roche. The compound is to be administered as a subcutaneous injection once weekly and is also effective given bi-weekly. It is a long acting 10% formulation of (Aib 8-35) human glucagon-like polypeptide-1 (7 - 36 amides) with 93% homology with the native polypeptide. It activates the glucagon-like polypeptide-1 receptor. Phase III trials are currently in process. OBJECTIVE: To provide a critical review of taspoglutide based on available published data. METHODS: Information provided from the search on Internet has been reviewed. A clinical interpretation is given on a background of practical experience as an investigator in a clinical trial with taspoglutide. RESULTS: Search on PubMed, EMBASE and Google gave hits on six clinical studies investigating taspoglutide of which the largest accounted for > 50% of the total study population. In addition, some animal studies were identified. Significant improvement on glucose control as well as several metabolic parameters has been shown with taspoglutide. DISCUSSION: Data from the clinical trials are interpreted in a medical context. The prospects of taspoglutide in the treatment of diabetes type 2 and metabolic syndrome are discussed. CONCLUSION: Taspoglutide is a new activator of the glucagon-like polypeptide-1 receptor. It is effective when injected once weekly and less effective when injected bi-weekly. In addition to its anti diabetic properties, taspoglutide has favorable effects on body weight and significantly reduces three of five diagnostic criteria for metabolic syndrome, namely glucose, waist circumference and fasting triglyceride.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Obesity and Diabetes in the Developing World — A Growing Challenge
Hossain, P., Kawar, B., & El Nahas, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmp068177 · Cited by 2,200
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
Garber, A., Henry, R., Ratner, R., Garcia-Hernandez, P. A., Rodriguez-Pattzi, H., Olvera-Alvarez, I., Hale, P. M., Zdravkovic, M., & Bode, B. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61246-5 · Cited by 1,057 · cited 1×
“There is no doubt that there is a strong need for new options for effective treatment of metabolic syndrome and overweight with the increasing prevalence, especially in young people [27].”
BackgroundCharbonnel, B., Karasik, A., Liu, J., Wu, M., Meininger, G., & for the Sitagliptin Study 020 Group (2006) · Diabetes Care · doi:10.2337/dc06-0706 · Cited by 790
Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., & for the Sitagliptin 036 Study Group (2007) · Diabetes Care · doi:10.2337/dc07-0627 · Cited by 509
Quality of Diabetes Care in U.S. Academic Medical Centers
Grant, R. W., Buse, J. B., Meigs, J. B., & for the University HealthSystem Consortium (UHC) Diabetes Benchmarking Project Team (2005) · Diabetes Care · doi:10.2337/diacare.28.2.337 · Cited by 311 · cited 1×
“Unfortunately, many anti diabetic compounds show decreased effect with chronic use and glycemic control also remains suboptimal with < 50% of patients achieving treatment goals [5].”
BackgroundExendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans
Schirra, J., Sturm, K., Leicht, P., Arnold, R., Göke, B., & Katschinski, M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1349 · Cited by 265
Cited by
Graaf, C. D., Donnelly, D., Wootten, D., Lau, J., Sexton, P. M., Miller, L. J., Ahn, J.-M., Liao, J., Fletcher, M. M., Yang, D., et al. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011395 · Cited by 403
Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
Gallwitz, B. (2011) · Drugs · doi:10.2165/11592810-000000000-00000 · Cited by 142
“[92] 5.2 Other Long-Acting GLP-1 Receptor Agonists in Development Albiglutide (GlaxoSmithKline Pharmaceuticals) is a humanGLP-1 receptor agonist with two molecules of GLP-1 linked to albumin.”
InfluentialIncretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
Koliaki, C., & Doupis, J. (2011) · Diabetes Therapy · doi:10.1007/s13300-011-0002-3 · Cited by 140
Novel GLP-1 receptor agonists for diabetes
Garber, A. J. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.638282 · Cited by 69
“homology with human GLP-1 [82] and is similar in structure to native GLP-1 except that it has two amino acid substitutions in positions 8 and 35 with aminoisobutyric acid, which render the molecule resistant to degradation by DPP-4 [24].”
BackgroundSun, F., Yu, K., Yang, Z., Wu, S., Zhang, Y., Shi, L., Ji, L., & Zhan, S. (2012) · Experimental Diabetes Research · doi:10.1155/2012/230624 · Cited by 58
Metadata
- Authors
- Retterstøl, K.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa UK Limited
- Published
- 2009-08-14
- Volume
- 18
- Issue
- 9
- Pages
- 1405-1411
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W2064413574
- Cited by
- 24
- References
- 7
- FWCI
- 4.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.